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Summary
This study has examined the cellular and humoral responses underlying the rejection ofrat renal
allografts bearing an isolated RTIAa class I MHC disparity. RTIAa disparate kidneys were
rejected promptly by high responder RTlu but not by low responder RT1° recipients (median
survival time 10 d and >100 d, respectively). The magnitude and phenotype of the cellular infiltrate
were similar in rejecting and nonrejecting RTIAa disparate kidneys. Paradoxically, graft infiltra-
ting cells and spleen cells from RT1° recipients showed minimal ability to lyse donor strain
lymphoblasts in vitro, whereas effector cells from RT1° recipients showed modest levels of
cytotoxicity. Injection of RTlu rats with MRC OX8 mAb was highly effective at selectively
depleting CD8+ cells from graft recipients but had no effect in prolonging the survival of RT1Aa
disparate grafts despite the complete absence of CD8+ cells from the graft infiltrate, which
included numerous CD4+ T cells and macrophages. RT1°, but not RT1°, recipients mounted
a strong alloantibody response against RT1Aa disparate kidneys. Immune serum obtained from
RTlu recipients that had rejected a RT1A° disparate graft was able, when injected into
cyclosporin-treated RTlu recipients, to restore their ability to reject a RT1Aa, but not a third-
party RT1°, kidney. These results suggest that CD8+ cells in general and CD8+ cytotoxic
effector cells in particular are unnecessary for the rapid rejection of RTIA2 class I disparate kidney
grafts by high responder RTlu recipients. By implication, CD4+ T cells alone are sufficient to
cause prompt rejection ofsuch grafts and they may do so by providing T cell help for the generation
of alloantibody.
S
tudies of the cellular response to allografts expressing iso-
lated class I or class II MHC disparities have contributed
substantially to current understanding of the relative roles
of CD4+ and CD8+ T cells in graft rejection (1-7). Adop-
tive transfer experiments in T cell-depleted mice bearing mu-
tant class I or class II disparate skin grafts have shown that
purified Lyt-2+ (CD8+) but not L3T4+ (CD4+) cells ini-
tiaterejection of class I disparate skin grafts, whereas L3T4+
but not Lyt-2+ cells initiate rejection of class II disparate
grafts (1-3). The contribution of CD8+ T cells to the re-
jection of mouse skin grafts bearing mutant or allelic class
I disparities has been confirmed by the demonstration that
treatment with anti-Lyt-2 to selectively deplete CD8+ T
cells prolongs graft survival (4, 6). Although selective deple-
tion of CD4+ T cells using anti-L3T4 does not prolong the
survival of skin grafts bearing an isolated class I disparity,
there is evidence that in some mouse strain combinations,
CD4+ T cells may also participate in the rejection of such
grafts (6) .
Most reports on the cellular effector response to isolated
class I disparate tissue relate to skin graft models in the mouse.
We chose to examine the immunological response to rat kidney
allografts differing at an isolated class I MHC antigen be-
cause it is likely that there are important differences in the
nature of the rejection response between indirectly vascula-
rized skin and directly vascularized organ grafts. In addition,
the rat renal allograft model enabled us to make a detailed
analysis of the phenotype and in vitro cytotoxic activity of
cells infiltrating the grafts. The rejection of allograftsbearing
the genetically isolated RT1Aa class I antigen is under strict
Ir gene control; the PVG RTl° and PVG RTlu strains are
low and high responders, respectively (8, 9). Using the ap-
propriate intra-MHC recombinant rat strains as kidney donors
we were therefore able to compare the cellular and humoral
response with rejecting and nonrejecting class I RT1Aa
kidney grafts.
Materials and Methods
Animals.
￿
The PVGcongenic and recombinant rat strains used
areshownin Table1 together with theirMHChaplotypes.Animals
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MHC Haplotype of PVG Congenic and Recombinant
Rat Strains
Animals are subsequently referred to by their haplotype name alone.
were obtained from Harlan Olac Ltd. (Bicester, Oxon, UK). Male
rats (8-16 wk old) were used throughout.
Kidney Transplantation.
￿
Kidneyswere transplanted into theleft
orthotopic site with end-to-end anastomosis of the renal artery,
renal vein, and ureter (13). The procedure was performed under
chloral hydrate anesthesia andischemic times were -25 min. For
graft survival studies, the recipient's right kidney was excised 7 d
after transplantation so that the continued survival of the trans-
planted animal was dependent on the function of the renal graft.
Graft function wasalso monitoredby performing sequential serum
urea and creatinine measurements.
Cprlosporin A Treatment.
￿
Rats received 15 mg/kgofcyclosporin
(a gift from Sandoz Pharmaceuticals), dissolved in olive oil, via a
gastric tube on the day of transplantation, and then daily for the
next 13 d.
Antibodies.
￿
The following mouse mAbs were used to label rat
leukocytes: MRC OX1 (leukocyte common antigen [14]); MRC
OX8 (CD8' T cytotoxicAuppressor lymphocytes and NK cells
[15]); W3/25 (CD4' T helper lymphocytes and some macro-
phages [15]); MRC OX12 (rat Ig tt chains on B lymphocytes [16]);
MRCOX19 (CD5 determinant on Tlymphocytes andthymocytes
[15]); and MRC OX21 (human C3b inactivator [17]) was used as
a negative control. ThesemAbs were kindly provided by Dr. D.W.
Mason and Prof. A.F. Williams (MRC Cellular Immunology Unit,
Sir WilliamDunn School ofPathology, Oxford, UK). Themouse
mAbs EDl, whichlabels most tissue macrophages, monocytes, and
dendriticcells (18); R73, whichrecognizes aconstant determinant
ofthe ratTCRa/S (19); andMRCOX18 andMRCOX6, which
recognize polymorphic determinants of MHC class I and class II
antigens, respectively (20), were obtained from Serotec Ltd., Ox-
ford, UK.
Production and In Vivo Treatment with mAh
￿
Hybridoma cells
secreting the antibodies MRC OX8 andMRCOX21 (a kind gift
ofProf. A.F. Williams andDr.D.W. Mason) were grown in tissue
culture medium andinjected intraperitoneally into pristane-primed
(DBA/2 x BALB/c)F, mice (Harlan Olac Ltd.) to produce as-
cites.Theimmunoglobulin contentof ascites wasquantified using
anti-mouse IgGl immunodiffusion plates and known mouse Ig
standards(Serotec Ltd.).Antibodies werediluted in PBSto 2mg/ml
and stored at -20°C. They were administered intraperitoneally
to recipient rats according to thefollowing schedule: 3mg on day
-1, 2mg on day0(day oftransplant), and 1 mgon days 3, 6, and9.
Cell Preparation and Fluorescence Analysis.
￿
Single cell suspensions
of lymph nodes and spleen were prepared as described previously
(21). PBL were separated by centrifugation of heparinized whole
blood over 75% iso-osmolar Percoll (Sigma Ltd., Poole, UK). For
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single-color fluorescence analysis, cellswere incubatedwith theap-
propriatemAb for 1 h at 4°C, washed twice in Dulbecco's A+ B
buffer (DAB)/0.2% BSA, andincubatedfor 1 hat 4°Cwith FITC-
conjugated F(ab')2 rabbit anti-mouse Ig (Dako Ltd., High
Wycombe, UK)containing 10% normal rat serumto prevent cross-
reaction of the antibody with rat Ig. For two-color fluorescence
analysis, thefirst stagewas as describedabove.Forthesecond stage,
unbound sites of the second antibody were blocked with MRC
OX21 (mouse anti-human C3b) andthecells were incubated for
30 minat 4°Cwithbiotinylated W3/25orbiotinylated MRCOX8
(a gift from Dr. E. Bell, Department of Immunology, University
ofManchester, UK)followed by aphycoerythrin-streptavidin com-
plex (BectonDickinson, Mountain View, CA). Cellswere washed
twice in (DAB)/0.2% BSA to remove excess antibodies. The la-
beled cells were analyzed on a FACScan flow cytometer (Becton
Dickinson).
Immunohistology. Kidney tissue was snap frozen in liquid
nitrogen and cryostat sections (5 um) were cut at -20°C onto
gelatinized slides. A range of mAbs was used to label the slides
using an indirect immunoperoxidase technique (22). A portionof
each kidney wasalso fixedin formalin, embedded in paraffin wax,
sectioned and stained with hematoxylin and eosin.
Morphometric Analysis of- Cellular Infiltrate.
￿
The area of each
immunoperoxidase-labeled tissue section infiltrated by leukocytes
of a particular phenotype was determined by morphometric anal-
ysis usingthepoint-counting techniqueas previously described(23).
Sections were examined at amagnificationof x400in the presence
ofamicroscope eyepiece graticule bearingasquared grid with 745
intersections. Foreach of 10 adjacent high powerfields, thenumber
of positively stained cells superimposed by an intersection was
counted and the percentage area of each section occupied by cells
of a particular phenotype was calculated as: 100 x [(number of
positive cellsundergrid intersections)/(total number ofgrid inter-
sections)]-
Harvesting of Graft Infiltrating Cells.
￿
Graft infiltrating cells
(GIC)' were harvestedfrom kidney allografts by a nonenzymatic
technique as describedpreviously (21). In brief, thefreshly excised
kidney allografts were finely diced, passed through a fine stainless
steelmesh and the mononuclear cellsseparated from the resulting
cell suspension by Percoll density gradient centrifugation.
Cell-mediated Cytotoxicity Assays.
￿
GIC and spleen cells from
transplantedrecipients were tested foralloantigen-specific cytotox-
icity andnonspecific cytotoxicity using astandard 6-h "Cr-release
assay essentially as described elsewhere (24). Alloantigen-specific
cytotoxicity was assessed using "Cr-labeled kidney donor strain
and third-party ConA-transformed splenicblasts as targets. The
mouselymphoma line YAC-1 (which is susceptible to NKcell-medi-
ated lysis) was also used as a target. Specific "Cr release was cal-
culated by the formula: percent specific release = 100 x [(ex-
perimental release - spontaneous release)/(maximum release -
spontaneous release)]. Data shown are the means of triplicate de-
terminations (spontaneous release <25% of maximum release in
all experiments).
Radioimmunoassay for Anti-RTIA° Antibodies. Antibodies
against RTIA' class I antigens were detected by a two-stage
bindingassayusingdonorstrain erythrocytes andradiolabeled sheep
anti-rat Ig (25). Serialdilutions of test sera in DAB/2% FCSwere
added, in duplicate 50-Al aliquots, to the wells of 96-well U-bot-
tomedmicrotiter plates (FlowLaboratories, Rickmansworth, UK)
that hadbeen pretreated with 2% BSA/DAB(toprevent nonspecific
binding ofIg). To each well, 50 Al of a 2% suspension ofwashed
1 Abbreviations used in thispaper . DAB, Dulbecco's A+Bbuffer; GIC, graft
infiltrating cells; MST, median survival time.
Rat Renal Allografts
RTl regions
Rat strain Haplotype A B/D C Reference
PVG RTl° c c c c -
PVG RTl' a a a a 10
PVG RTl° u u u u 10
PVG R1 rl a c c 11
PVG R8 r8 a u u 12" Number of animals in group.
t Contralateral nephrectomy performed on day 7.
S Median survival time.
rat erythrocytes was added and the plates were incubated for 1 h
at room temperature and then washed four times in DAB/FCS.
Next, 100 ul '211-conjugated F(aV)z sheep antibodies against rat
Ig (AmershamInternational, Amersham, UK)was added (ensuring
at least 50,000 cpm/well) andtheplates were incubated forafur-
ther 1 h. The erythrocytes were then washed afurther four times,
transferred to tubes, andthecell bound radioactivity wascounted.
Lpmphocytotcaric Antibody Deteminations
￿
Test sera were incubated
with 5'Cr-labeled Con A-transformed splenic blast targets in the
presence ofguinea pigcomplement (Sera-Lab, Sussex, UK)or fresh
rat serum in acytotoxicity assay as follows. Serial dilutions of test
sera in RPMI/10 mM Hepes/5% FCS were prepared in 96-well
U-bottomed microtiter plates in duplicate aliquots of 50 gl. "Cr-
labeled Con A-transformed splenicblasts at 106perml in RPMI/
Hepes/FCS were added to each well, and incubated at 37°C for
30 min. 100Al guinea pigcomplement (Sera-Lab) or freshratserum,
appropriately diluted, were added and incubated for 1 h at 37°C.
Plates were then centrifuged briefly, and 100-Id aliquots of super-
natant were transferred to tubes forcounting released "Cr. Specific
"Cr releasewas calculated by theformula: Percent specific release
= 100 x [(experimental release - spontaneous release)/(maximum
release - spontaneous release)].
Results
Rejection ofRenal Allografts Bearing an Isolated RnA' Class
I MHC Disparity. Rejection of RTlA' incompatible skin
andorgan grafts is understrict MHC-linked immune response
gene control (8, 26, 27). The PVG RT1" strain is a high re-
sponder to class I RTIA' incompatible grafts from the PVG
R8 donor whereas the PVG RT1° strain is a low responder
to RTIA' incompatible grafts from PVG Rl animals. This
wasconfirmed here for renal allografts (Table 2). R8 kidneys
were rapidly rejected by RTl° recipients, which died shortly
after contralateral nephrectomy (MST 10 d) with markedly
raised serum urea and creatinine levels. Grafts excised5 d after
transplantation already showed histological features of severe
rejection, with widespread vascular damage and associated
intravascular fibrin and platelet deposition. Focal tubular
necrosis and ischemia of glomeruli were present and there
was an interstitial mononuclear cell infiltrate. By day 7, ex-
tensive interstitial hemorrhage was apparent and grafts had
frequently undergone complete infarction. In contrast, R1
Table 3.
￿
Magnitude and Phenotype of Cellular Infiltrate and Expression ofMHC Antigens in Renal Allografts
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Class II MHC expressiont
Renal Arteriolar
tubules endothelium
Kidneys were excised on day 5 after transplantation and cryostat sections were labeled using the immunoperoxidase technique.
' Thepercentage area infiltrate was determined by point counting with a microscope eye piece graticule. Values are mean ± SD of five allografts.
Results in brackets represent the phenotype as a percentage of the total area of the cellular infiltrate (i.e., percent of OX1 are an infiltrate).
t Class I and class II MHC expression was determined by labeling with MRC OX18 and MRC OX6, respectively. In all allografts the vascular
endothelium andrenaltubuleswere strongly class Ipositive. Staining for class II MHC antigens wasas shown: -, no staining; +/- , very occasional
weak staining; +, weak staining; + +, strong staining.
Percentage area occupied by infiltrate'
Group Donor Recipient
MRC OX1
(L-CA)
MRC OX8
(CD8)
W3/25
(CD4)
ED1
(MO)
1 r8 u 16 ± 10 (100%) 6 ± 1 (38%) 2 ± 1 (13%) 10 ± 6 (63%)
2 rl c 18 ± 1 (100%) 7 ± 2 (39%) 6 ± 2 (33%) 9 ± 1 (50%)
3 a c 52 ± 12 (100%) 16 ± 11 (31%) 9 ± 6 (17%) 23 ± 8 (44%)
4 c c 4 ± 1 <1 3 ± 1 <1
Table 2. Rejection of Rat Renal Allografts Bearing Isolated MHC Subregion Disparities
Group Donor Recipient Incompatibility n' Recipient survival$ MSTS
d d
1 r8 u A' 6 10, 10, 10, 10, 10, 11 10
2 rl c A' 6 All > 100 >100
3 a c A' B/D' C' 5 10, 10, 10, 10, 17 10kidneys survived indefinitely in RT1c recipients (MST >100
d) and serum urea and creatinine levels remained normal
throughout. Rl grafts showed mononuclear cell infiltration
but no evidence of renal parenchymal damage. The influence
of Ir gene control on renal allograft survival was not apparent
when an isolated A' class I disparity was replaced by a full
haplotype RT1a MHC disparity since low responder RT1c
animals rapidly rejected RT1' kidneys (MST 10 d).
Magnitude and Phenotype of Cellular Infiltrate in RTIAa Dis-
parate Grafts. The demonstration that class I RT1Aa in-
compatible kidneys were rapidly rejected by RT1n recipients
but not by RT1° recipients led us to compare the intragraft
cellular responses. Our first approach was to assess the mag-
nitude and phenotype of the cellular infiltrate within the grafts.
Cryostat sections ofkidney allografts were labeled with a range
of mouse anti-rat mAbs by an indirect immunoperoxidase
technique and infiltrates assessed by morphometric analysis
(Table 3). Both rejecting R8 grafts in RTl° recipients and
nonrejecting R1 grafts in RT1c recipients showed a diffuse
interstitial mononuclear cell infiltrate with perivascular
mononuclear cell aggregates. The magnitude of cellular
infiltration (determined by OXl) was similar in rejecting and
nonrejecting grafts. The infiltrate in class I disparate grafts
was fourfold greater than that observed in grafts between
syngeneic animals, but substantially less than that found in
rejecting grafts bearing a full haplotype RT1a disparity. The
phenotype of the cellular infiltrate in rejecting and nonrejecting
RT1A' disparate grafts was similar. CD8+ cells formed a
large component of the total infiltrate but the predominant
cell type was the macrophage (ED1+). CD4+ and CD8+
cells were distributed homogeneously within the infiltrate
and there was no preferential localization of either pheno-
type to specific areas of the graft.
Cytotoxic RepertoireofGICand Splenocytes in Recipients with
RTIAa Disparate Grafts. Butcher and Howard showed that
high responder RTl" rats bearing RT1Aa incompatible skin
grafts develop rytotoxic T cells in the draining lymph nodes
and that generation of such cells is impaired in low responder
RT1c rats (8) . We predicted, therefore, that GIC from re-
jecting RT1Aa disparate kidneys in RTlu recipients would,
when tested in vitro, demonstrate higher levels of specific
anti-donor rytotoxic activity than cells obtained from non-
rejecting RT1A° grafts in RT1c recipients, thereby reflecting
a role for cytotoxic T cells in the rejection response of these
class I disparate grafts. To test this, the rytotoxic activity of
GIC and spleen cells from these animals was studied in 6-h
51Cr-release assays. The results of representative experiments
are shown in Fig. 1. Unexpectedly, GIC obtained from re-
jecting RTlAa incompatible R8 kidneys in high responder
RT1° recipients showed minimal ability to lyse Con A blasts
of the kidney donor strain. Paradoxically, GIC from non-
rejecting RT1A' disparate R1 grafts in low responder RT1c
recipients often showed modest levels of cytotoxicity against
donor strain lymphoblasts. However, this cytotoxicity was
not entirely donor specific, since lysis of third-party Con A
blasts was also apparent. As expected, full MHC disparate
rejecting RT1a grafts in RT1c recipients were infiltrated by
cells that demonstrated high levels of donor-specific in vitro
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effector : target ratio
61 251 100:1 6:1 25:1 100:1 61 25:1 100:1
a-c
6:1 25:1 100:1 6:1 25:1 100:1 6:1 25:1 100:1
Figure 1.
￿
Cytotoxicity of graft infiltrating cells (a) and spleen cells (b)
from renal allograft recipients 5 d after transplantation. GIC were recov-
ered by mechanical disaggregation of excised kidneys (0.5-2 x 107 cells
obtained per graft) and together with spleen cells were used as effectors
in 6-h S'Cr-release assays. The results show typical curves for lysis of
targets by cells obtained from RT1u recipients bearing rejecting R8 grafts,
RTic recipients bearing nonrejecting RI grafts, and RTlc recipients bearing
rejecting RTla grafts. Targets are represented as follows: donor strain Con
A blasts (N), third-party (RT11) Con A blasts ("), syngeneic Con A
blasts (*), andYAC-1 (A). For each strain combination, at least six sepa-
rate experiments were performed with similar results.
cytotoxic activity. This last result is important sinceit confirms
that the specific cytotoxic activity ofGIC, when it is present,
can be readily detected under the in vitro conditions used
in these experiments. GIC from all grafts were able to lyse
the NK-susceptible target YAC-1 but levels of cytotoxicity
were lowest in rejecting RTlAa incompatible grafts.
The cytotoxic activity ofspleen cells from the graftrecipients
was also tested and showed the same general pattern as that
already described for GIC. As before, the most notable ob-
servation was the inability of effector cells, from RTl°
recipients bearing a rejecting RT1Aa disparate R8 graft, to
show significant levels of specific killing of donor lympho-
blasts (donor specific lysis was <10% in all of 10 recipients
tested).
Effect ofAnti-CD8 (MRC OX8) Antibody on RenalAllograft
Rejection. The finding that class I incompatible R8 kidneys
were rapidly rejected by high responder RT1° recipients but
that the graft infiltrate, when tested in vitro, showed little
ability to lyse donor strain target cells led us to questionC
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Figure 2.
￿
FACS profiles ofPBL
from normal RT11 rats (row a)
andRTIu rats 6d (row b) or 14 d
(rowc) after starting in vivo treat-
ment with MRC OXS(according
to the schedule described in
Materials and Methods). PBL
were stained with FITC anti-
mouse Ig alone, MRC OX8 and
FITC anti-mouse Ig, or W3/25
and FITC anti-mouse Ig. FACS
analysis ofLNCgavecomparable
results.
_ 0.396
Figure 3.
￿
FACS analysis ofPBL from normal RT1u
rat (a andb) andUP rat 5d after starting treatment
with MRC OX8 (c and d).whether CD8 effector cellsplay an essential role in the rejec-
tion of RTIA' disparate grafts. We therefore specifically
depleted CD8+ cells from RTlu rats, by in vivo treatment
with the mAb MRC OX8, and then examined their ability
to reject RTIA° kidneys.
FACS analysis (Fig. 2), together with immunohistology
(results not shown), indicated that after MRC OX8 treat-
ment was started, (according to the protocol described in
Materials and Methods), CD8' cells were undetectable in
the blood, lymph nodes, and spleen of RTlu rats for at least
14 d. This was not due to masking of the CD8 antigen
by antibody coating since mouse Ig was not detectable on
the surface of lymphoid cells. Loss of CD8+ cells was as-
sociated with a corresponding increase in the relative frequency
of residual CD4+ T cells and MRC OX12+ B cells.
Confirmation that MRC OX8 treatment caused depletion
of CD8+ cells rather than modulation of the CD8 antigen
was obtained by dual staining with R73 (which labels the
TCR-ci//3) and either MRC OX8 or W3/25 (Fig. 3). After
in vivo treatment with MRC OX8, the CD8+ TCRci/Q+
cell population was completely eliminated and all residual
TCR-a/o+ cells coexpressed the CD4 antigen.
Although MRC OXS treatment depleted CD8+ cells
from RT1° rats, it had no effect on their ability to reject
RTIA' class I disparate renal allografts (Table 4). Survival
times for graft recipients given MRC OX8 were the same
as those for recipients treated either with MRC OX21 (con-
trol mAb) or left untreated (MST 10 d in all groups) . Rejec-
tion in MRC OX8-treated recipients was accompanied by
mononuclear cell infiltration of the graft together with a T
cell-dependent anti-RTIA' cytotoxic alloantibody response
(similar to that found in untreated recipients, results not
shown) . The CD8+ infiltrate previously observed in re-
jecting RTIA' disparate grafts from untreated recipients was
completelyabsent from rejecting grafts in MRC OX8-treated
animals (Fig. 4, a and b). Much o£the residual infiltratecom-
prised macrophages, as shown by labeling with EDl (Fig.
4 c). There were also numerous T cells within the graft, as
shown by expression of the TCR-ci/0 (Fig. 4 d). Two-color
FACS analysis of the harvested GIC confirmed that this cell
population consisted exclusively of TCRci/a+ CD4+ T
cells (results not shown) .
Table 4.
￿
Inability of AMC OXS Treatment to Prevent Rejection of RTIA° Disparate Renal Allografts
Group Donor Recipient
1552
mAb treatment'
1
￿
r8
￿
u
￿
MRC OX8
MRC OX21 (control)
Alloantibody Levels in Recipients Bearing Class IIncompatible
Grafts. Ir gene control is known to have a strong influence
not only on graft survival but also on the production of
T-dependent anti-RTIA' alloantibody (9). This influence
was readily apparent in the present experiments. High re-
sponder RTlu recipients developed a strong anti-RTIA' an-
tibody response to R8 kidney grafts as detected by a two-
stage binding assay usingdonor strain erythrocytes '(Fig. 5).
In contrast, low responder RT1° recipients showed a min-
imal antibody response to class I incompatible Rl grafts.
When the sera from grafted animals were assayed for cyto-
toxic antibody, RT1° recipients showed a progressively in-
creasing anti-RTla antibody response detectable from day 3
after transplantation, whereas cytotoxic antibody in RT1°
recipients was barely detectable on any day after transplanta-
tion (Fig. 6). The cytotoxic antibody in RTlu recipients was
specific for the RTIA' haplotype since it failed to lyse third-
party RTl° target cells (results not shown) . The high levels
of cytotoxic antibody in the serum of RT1° graft recipients
were initially demonstrated by assays in which guinea pig
serum was used as a source of complement. Fresh syngeneic
RT1° rat serum was also effective as a complement source
in these assays (Fig. 7). In contrast, RT1c rat serum was not
only ineffective but when mixed with RTlu serum appeared
to inhibit its effectiveness as a complement source. The ex-
planation for this unexpected difference is unclear and the
phenomenon is currently being investigated further in our
laboratory although one possibility is polymorphism in class
III MHC gene products between the u and c MHC haplotypes.
Passive Transfer Experiments.
￿
To determine whether alloan-
tibody played a role in the rejection of RTIA' disparate
kidney grafts by RTlu recipients, a series of passive transfer
experiments was undertaken (Table 5). Immune serum for
passive transfer was obtained from RTlu rats bearing a re-
jecting R8 kidney graft 5, 6, or 10 d after transplantation.
Intravenous injection of immune serum into low responder
RT1c recipients of R1 kidneys did not cause graft rejection
(MST >50 d, no increase in serum urea or creatinine). This
result did not, however, exclude a role for cytotoxic alloanti-
body in the rejection of RTIA' disparate grafts by high re-
sponder RTlu recipients because, as already noted, RT1c rat
serum (in contrast to RTlu serum) was not effective as a
n
￿
Recipient survival#
￿
MSTS
d
￿
d
6
￿
9, 9, 10, 10, 10, 10
￿
10
4
￿
10, 10, 10, 10
￿
10
Recipient rats were treated in vivo with either MRC OX8 or MRC OX21 (control). mAbs were given intraperitoneally on days -1, 0, 3, 6,
and 9 as described in Materials and Methods.
t Contralateral nephrectomy performedon day 7.
S Median survival time.
Rejection of RTIA° Disparate Rat Renal Allograftscomplement source for assaying the in vitro cytotoxicity of
RTlu anti-RTIAa antibody. The ability of immune serum
to cause renal allograft rejection in cyclosporin-treatedUP
recipients was therefore tested (Table 5) . Treatment ofRTlu
rats with cyclosporin for 14 d prevented them from rejecting
O
X
a
U
5
4
3
2
1
0
a
reciprocal dMons of sera
Figure 5.
￿
Antibody response to RTIA2 disparate renal allogmfts. Serum
was obtained on days 1, 3, 5, 7, and 10 after renal transplantation, titrated
against donor strain erythrocytes, and binding was detected with 1251 sheep
anti-rat Ig. (a) RTlu recipients of RS renal allogmfts and (b) RTlc
recipients of RI renal allografts. Values shown are mean of four graft
recipients .
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R8 kidney grafts (MST > 50 days) and also abrogated their
antibody response to these grafts (results not shown) . Injec-
tion ofday 10 (but not day 5/6) immune serum restored the
ability of cyclosporin treated RTlu rats to promptly reject
a R8 kidney (MST 9 d) . This effect ofimmune serum was
Figure 4. Immunohistological
analysis ofthe leukocyte infiltrate in
rejecting RTIA2 disparate RS kid-
neys removed at day 5 from RTlu
recipients. Cryostat sections were la-
beled with mAbs using the im-
munoperoxidase technique, lightly
counterstained with hematoxylin
and photographed using a green
filter to enhance the contrast ofthe
permddase reaction product . All sec-
tions x 160. (a) Rejecting R8
kidney from unmodified RTlu re-
cipient, labeled with MRC OX8.
Note perivascular aggregate and
scattered CD8* infiltrate. (b-d)
Rejecting R8 kidney from RTlu
recipient treated in vivowithMRC
OX8; (b) labeled withMRCOX8,
note complete absence of CD8
cells; (c) labeled with EDI, note the
relatively large number of macro-
phages; and (d) labeled with R73
(antiTCR-a/g), note perivascular
and interstitial T cell infiltrate.
Figure 6.
￿
Cytotoxic antibody response to RTIAa disparate renal al-
lografts. Serumwas obtained ondays 1, 3, 5, 7, and10afterrenal transplan-
tation and assayed against SICr-labeled donor strain ConA blasts in the
presence of guinea pig complement . (a) RTlu recipients ofR8 renal al-
lografts. (b)RTl- recipients of R1 renal allografts. Values shown aremean
of four graft recipients .2 4 a is
reciprocal diludons
of complement
￿
(' )
allospecific since injection of anti-RTlAa immune serum
into cyclosporin-treated RTlu rats bearing a RT1° kidney did
not cause graft rejection (MST > 50 d). The histopatholog-
ical appearance of class I disparate grafts rejected in the pres-
ence of passively transferred immune serum was broadly similar
to that of RT1Aa disparate grafts undergoing rejection in
unmodified RTlu recipients. Damage to the graft vascula-
ture was a major feature and neutrophil margination and
infiltration (a characteristic feature of hyperacute rejection)
was not apparent .
Discussion
Rat renal allografts bearing an isolated RTla class I dis-
parity are rejected promptly by high responder UP but not
Figure 7.
￿
Complement-medi-
ated cytotoxicity of s'Cr-labeled
R8 Con A blasts by RTlu anti
R8 immune serum (day 5 after
transplant). The assay was per-
formed in the presence of guinea
pigcomplement (A), freshRTlu
(/), RTIc ("), or RTIu +
RT1c (50:50mixture) rat serum
by low responder RT1° recipients. In this report we have
shown that class I-restricted cytotoxic CD8+ effector cells
are not necessary for the rejection of RTIAa disparate kidney
grafts by UP recipients. This finding for class I disparate
kidney grafts is ofinterest because most reports on the rejec-
tion of class I disparate skin or heart allografts in the rodent
have emphasized the importance of the CD8+ T cell subset.
Experiments in mice have shown that Lyt-2+ T cells play
a major role in the rejection of class I disparate skin grafts,
whereas L3T4+ cells may, depending on the strain combi-
nation, be unnecessary (1-6). Similarly, using a rat model,
Lowry et al. (7) reported an absolute requirement for CD8+
cells in the rejection ofclass I disparate heart grafts by acutely
irradiated rats, and in addition, suggested that this related
to their role as cytotoxic effector cells. Moreover, congeni-
tally athymic rats of low responder RTl° haplotype can only
be induced to reject RTIA2 class I disparate skin grafts by
the adoptive transfer ofboth CD4+ and CD8+ T cells (28).
It has been recently shown that low responder RTl° and
high responder RT1u rats have a similar frequency of anti-
RT1Aa T cytotoxic precursor cells and that the frequency of
such cells increases in RTlu but not RT1c recipients of a
class I RTIA' disparate cardiac allograft (29). In the present
study it is notable, therefore, that GIC harvested from re-
jecting RTlAa class I disparate kidney grafts showed min-
imal in vitro cytotoxicity towards donor strain lymphoblasts.
Since in this and previous studies (23), we were able to dem-
onstrate readily, the presence of substantial levels of specific
cytotoxicity in rejecting grafts differing from their host at
the entire (class I and class II) MHC locus the apparent ab-
sence of significant cytotoxicity in RTIAa class I disparate
grafts led us to question whether class I-restricted cytotoxic
effector cells played a necessary role in their rejection. Ac-
cording to the orthodox view, class I-restricted cytotoxic cells
would bear the CD8+ phenotype (30). We therefore tested
' Contralateral nephrectomy on day 7.
t Immune serumwas obtained from RTlu recipients bearing rejecting R8 kidneys 5, 6, or 10 d after transplantation. After heat inactivation (56°C
for 30 min) it was stored at -20°C and microfuged before use. 1 ml of immune serum (or normal RTlu serum) was given to graft recipients
by i.v. injection on days 1, 2, 3, 4, and 5 after transplantation.
S Cyclosporin was given daily (15 mg/kg) by gavage for 14 d after transplantation.
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Table 5.
Group
Passive Transfer
Donor
Experiments
Recipient Treatment n Recipient survival" MST
d d
1 rl c Normal serum 3 All >50 >50
2 rl c Day 5/6 immune serumt 4 All >50 >50
3 rl c Day 10 immune serum 4 All >50 >50
4 r8 u Cyclosporins + normal serum 6 All >50 >50
5 r8 u Cyclosporin + day 5/6 immune serum 6 All >50 >50
6 r8 u Cyclosporin + day 10 immune serum 5 9, 9, 9, 9, 10 9
7 c u Cyclosporin + day 10 immune serum 4 38, >50, >50, >50 >50
8 c u None 4 91 10the effect of depleting CD8+ cells from RTlu rats on their
ability to reject an RTIA' disparate kidney. Injection of the
mAb-MRC OX8 is highly effective at specifically depleting
CD8+ cells from treated rats (31-33). The loss of CD8+
cells is accompanied by a functional loss of specific alloreac-
tive cytotoxicity and a marked reduction in NK cell activity
(many rat NK cells are CD8+). In the present study, the
MRC OX8 treatment schedule completely depleted CD8+
cells from the peripheral blood and lymphoid tissue of RTlu
rats'for at least2 wk afterstarting treatment. However, MRC
OX8-treated RT1u rats showed no impairment in their
ability to reject RT1A' renal allografts despite the complete
absence of CD8 + GIC from the rejecting kidneys. There-
fore, whereas CD8+ T cells may or may not contribute to
the rejection of RT1A' disparate kidneys in unmodified
RTlu recipients, their participation is not essential for the
rejection of such grafts.
Since rodents deficient in both CD4+ and CD8+ lym-
phocytes are unable to reject allografts, our results suggest
that the CD4+ T cell subset is both able and sufficient to
induce rejection ofclass I disparate renal allografts. Moreover,
CD4+ cells appear to be essential for RT1u rats to reject
RT1A' disparate kidneys promptly, since we have recently
shown that depletion of CD4+ T cells by in vivo treatment
with the mAbs MRC OX35 plus MRC OX38, given ac-
cording to a previously described protocol (34), prevents re-
jection for at least several weeks (Porteous, C., E.M. Bolton
and J.A. Bradley, manuscript in preparation).
Because CD4+ T cells are class II restricted, they would
not be expected to recognize allo-class I MHC molecules
directly, although exceptional CD4+ T cell clones have been
described that are lytictowards classI MHC targets (35, 36),
and therefore direct recognition of class I molecules by
CD4+ cells cannot be completely discounted. However, the
contemporary view is that class I-restricted CD4+ T cells
recognize allo-class I antigen that is processed and presented
in the context of self class II MHC. With reference to the
present experiments this implies that RTlu CD4+ T cells
recognize A' antigen that has been processed, either by
donor or host antigen-presenting cells, and is presented in
the context of RTIB/Du class II MHC molecules.
The question arises as to the mechanism whereby CD4+
T cells activated in this way are able to mediate rejection of
class I disparate kidney grafts. Numerous CD4+ T cells were
identified within rejecting kidneys in MRC OX8-treated
recipients, and in principal, they couldmediate graft damage
by recruiting and activating nonspecific cellular effectors in
a classical DTH reaction. However, neither the immunohisto-
logical nor the functional comparison of GIC in rejecting
and nonrejecting classI disparate kidneys supported this sug-
gestion. Although macrophages were a major component of
the cellular infiltrate in rejecting class I disparate grafts, they
were also present in similar numbers in nonrejecting grafts.
In addition, GIC harvested from nonrejecting grafts showed
greater levels of in vitro cytotoxicity against target cells sus-
ceptible to NK cell-mediated lysis.
It is not possible, from these observations alone, to com-
pletely exclude a role for DTH in mediating rejection of class
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I disparate kidney grafts. However, there is convincing evi-
dence, at least in the case of skin allografts, that the tissue
destruction accompanying rejection is exquisitely specific (37,
38), implying that either antigen-specific effector T cells or
else alloantibody are responsible for graft rejection.
In a vascularized allograft, the microvasculature is likely
to be a critical target of the effector responses (39, 40) and
the early vascular injury followed by ischemia and hemor-
rhage in the rejecting class I disparate renal allografts in the
present experiments points to the vascular endothelium as
being the major target ofthe rejection process. It is interesting
to speculate that the requirements for an antigen-specific
effector cell could be fulfilled by a class 11-restricted CD4+
T cell able to recognize allo-class I peptides, presented in the
context of self class II MHC by donor endothelial cells. Al-
though damage ofvascular endothelium by syngeneic antigen-
specific CD4+ effector cells has a precedent in the rat model
of experimental allergic encephalomyelitis (41), the sugges-
tion that a CD4+ effector T cell is directly responsible for
the rejection of class I disparate kidney grafts is made less
likely by the observation that the vascular endothelium in
these rejecting grafts remains largely class 11-negative (see
Table 3).
The results of the present experiments are most consistent
with the notion that CD4+ T cell-dependent alloantibody
plays a decisive role in the rejection of RT1A' disparate
kidney grafts by high responder RT1u recipients. Antibody
could, in principal, mediate tissue damage through antibody-
dependent cellular cytotoxicity or by complement activation,
resulting in endothelial activation and injury, release ofkinins
and vasoactive peptides, and activation ofthe coagulation cas-
cade. Indirect evidence that alloantibody may play a role in
rejection was provided by the close correlation between the
development of a strong RT1A' antibody response and graft
rejection in RT1u recipients. The histopathological appear-
ances of rejecting RT1A' kidneys were also consistent with
antibody-mediated damage of the graft microvasculature since
the endothelial injury occurred in the absence of significant
infiltration of the vessel walls by mononuclear cells. Direct
evidence that circulating anti-RTlA' antibody was capable
of causing renal allograft damage in vivo was provided by
the demonstration that passive transfer ofimmune serum was
able to restore the ability of cyclosporin-treated RTlu re-
cipients to reject RT1A' disparate but not third-party RTl°
kidney grafts. Moreover, the histopathological appearanceof
these rejecting kidneys was similar to that seen in RTIA'
disparate grafts undergoing rejection in unmodified RTlu
recipients. The inability of passively transferred anti-RTlA-
immune serum to cause rejection of RTIAa disparate kidney
grafts in low responder RTl° rats is intriguing and may be
attributed in part to the apparent differences in complement
activity between the RTlu and RT1° rat strains.
The role ofalloantibody in acute rejection is controversial
and it is generally accepted that cellular rather than humoral
effector mechanisms are responsible for rejection of allogeneic
grafts by unsensitized recipients. Adoptive transfer experi-
ments in acutely irradiated rats have shown that purified T
cells are able to restore rejection ofboth fully allogeneic (42,43) and class I disparate (7) heart grafts in the absence of
detectable circulating cytotoxic antibodies in the recipient.
The results reported here for RTlA' class I disparate kidney
allografts are therefore of interest because they suggest that
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